OHR Pharmaceutical Inc.

Ohr Pharmaceutical to Present at the Cowen & Company 37th Annual Health Care Conference

Download PDF

NEW YORK, March 02, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that Jason Slakter, MD, Chief Executive Officer, will provide a corporate overview at the Cowen & Company 37th Annual Health Care Conference, taking place March 6-8 at the Boston Marriott Copley Place in Boston Massachusetts.

Ohr Pharmaceutical Presentation Details    
Date: Monday, March 6
Time:  4:40pm Eastern Time
Location:                 Regis Ballroom, 3rd Floor

About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (OHRP) is an ophthalmology research and development company. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as Squalamine or OHR-102), is currently being studied as an eye drop formulation in a clinical trial for the treatment of the wet form of age-related macular degeneration.  In addition, Ohr has a sustained release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.

Ohr Pharmaceutical Inc. 
Investor Relations  

LifeSci Advisors, LLC
Michael Wood

Primary Logo

Source: Ohr Pharmaceutical, Inc.